FENC240719C7500
- 0.10
- 0.000.00%
Fennec Pharmaceuticals Newsroom
Fennec Pharmaceuticals Analyst Ratings
Fennec Pharmaceuticals Analyst Ratings
Maintained Buy Rating for Fennec Pharmaceuticals Amidst Revenue Growth and Strategic Partnerships
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and BioLife Solutions (BLFS)
Fennec Pharmaceuticals (FENC) Gets a Buy From Capital One Financial
Buy Rating Reaffirmed for Fennec Pharmaceuticals Following Strategic European Licensing Deal and Strong Financial Outlook
Fennec Pharmaceuticals Analyst Ratings
Buy Rating for Fennec Pharmaceuticals Amidst Strong Pedmark Sales and Market Expansion Potential
Fennec Pharmaceuticals Analyst Ratings
Capital One Financial Sticks to Their Buy Rating for Fennec Pharmaceuticals (FENC)
Buy Rating for Fennec Pharmaceuticals Amid Strong Pedmark Sales and Market Expansion Potential
Fennec Pharmaceuticals (FENC) Gets a Buy From Craig-Hallum
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Societal CDMO (SCTL)
Analysts Conflicted on These Healthcare Names: Roche Holding AG (OtherRHHVF), REPRO-MED Systems (KRMD) and Fennec Pharmaceuticals (FENC)
Craig-Hallum Reaffirms Their Buy Rating on Fennec Pharmaceuticals (FENC)
Fennec Pharmaceuticals' Strong Financial Performance and Global Expansion Opportunities Validate Buy Rating
Craig-Hallum Reaffirms Their Buy Rating on Fennec Pharmaceuticals (FENC)
Fennec Pharmaceuticals (FENC) Receives a Buy From Craig-Hallum
Maxim Group Keeps Their Buy Rating on Fennec Pharmaceuticals (FENC)
Fennec Pharmaceuticals Analyst Ratings